Literature DB >> 25594858

Novel microdeletions affecting the GNAS locus in pseudohypoparathyroidism: characterization of the underlying mechanisms.

Intza Garin1, Francesca M Elli, Agnes Linglart, Caroline Silve, Luisa de Sanctis, Paolo Bordogna, Arrate Pereda, Joe T R Clarke, Caroline Kannengiesser, Regis Coutant, Yardena Tenebaum-Rakover, Osnat Admoni, Guiomar Perez de Nanclares, Giovanna Mantovani.   

Abstract

CONTEXT: Pseudohypoparathyroidism type Ia (PHP1A) is a rare endocrine disorder characterized by hypocalcemia, hyperphosphatemia, multiple hormonal resistance, and features of Albright hereditary osteodystrophy. When the phenotype is present but not associated with hormonal resistance, it is called psedopseudohypoparathyroidism (PPHP). Both entities have been associated to GNAS haploinsufficiency, and are mostly caused by inherited inactivating mutations at GNAS gene that codes for the stimulatory alpha subunit of G protein, although the cause remains unidentified in approximately 30% of patients.
OBJECTIVES: The aims of our work were 1) to identify GNAS locus defects in 112 patients with clinical diagnosis of PHP1A/PPHP and no point mutations at GNAS, to improve molecular diagnostic and genetic counseling; 2) to outline the underlying molecular mechanism(s).
METHODS: Methylation-specific-multiplex ligation-dependent probe amplification, qPCR, array comparative genomic hybridization, and long-PCR were used to search for genomic rearrangements at chromosome 20q and to identify their boundaries. We used different bioinformatic approaches to assess the involvement of the genomic architecture in the origin of the deletions.
RESULTS: We discovered seven novel genomic deletions, ranging from 106-bp to 2.6-Mb. The characterization of five of seven deletion breakpoints and the definition of the putative molecular mechanisms responsible for these rearrangements revealed that Alu sequences play a major role in determining the genetic instability of the region.
CONCLUSION: We observed that deletions at GNAS locus represent a significant cause of PPHP/PHP1A and that such defects are mostly associated with Alu-mediated recombination events. Their investigation revealed to be fundamental as, in some cases, they could be misdiagnosed as imprinting defects.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25594858     DOI: 10.1210/jc.2014-3098

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  A novel deletion involving GNAS exon 1 causes PHP1A and further refines the region required for normal methylation at exon A/B.

Authors:  Monica Reyes; Anara Karaca; Murat Bastepe; Nese Ersoz Gulcelik; Harald Jüppner
Journal:  Bone       Date:  2017-07-12       Impact factor: 4.398

Review 2.  Pseudohypoparathyroidism and Gsα-cAMP-linked disorders: current view and open issues.

Authors:  Giovanna Mantovani; Anna Spada; Francesca Marta Elli
Journal:  Nat Rev Endocrinol       Date:  2016-04-22       Impact factor: 43.330

Review 3.  A severe inactivating PTH/PTHrP signaling disorder type 2 in a patient carrying a novel large deletion of the GNAS gene: a case report and review of the literature.

Authors:  Alessandro Brancatella; Giovanna Mantovani; Francesca M Elli; Simona Borsari; Claudio Marcocci; Filomena Cetani
Journal:  Endocrine       Date:  2020-01-14       Impact factor: 3.633

4.  Mosaicism for GNAS methylation defects associated with pseudohypoparathyroidism type 1B arose in early post-zygotic phases.

Authors:  Francesca Marta Elli; Paolo Bordogna; Maura Arosio; Anna Spada; Giovanna Mantovani
Journal:  Clin Epigenetics       Date:  2018-02-06       Impact factor: 6.551

5.  What to consider when pseudohypoparathyroidism is ruled out: iPPSD and differential diagnosis.

Authors:  Arrate Pereda; Intza Garin; Guiomar Perez de Nanclares
Journal:  BMC Med Genet       Date:  2018-03-02       Impact factor: 2.103

6.  Intragenic Deletions of GNAS in Pseudohypoparathyroidism Type 1A Identify a New Region Affecting Methylation of Exon A/B.

Authors:  Dong Li; Caleb Bupp; Michael E March; Hakon Hakonarson; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

Review 7.  Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients.

Authors:  Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Aurora Garcia Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen A T Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Manasori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebeca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart
Journal:  Horm Res Paediatr       Date:  2020-08-05       Impact factor: 2.852

Review 8.  Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.

Authors:  Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; Alessia Usardi; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Kathleen Freson; Aurora García Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Marie-Laure Kottler; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Masanori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebecca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart
Journal:  Nat Rev Endocrinol       Date:  2018-08       Impact factor: 43.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.